|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
|
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Deferred transaction costs | ||||
| Cash and cash equivalents | ||||
| Accounts receivable, net | ||||
| Prepaid expenses and other current assets | ||||
| Total current assets | ||||
| Equipment, net | ||||
| Operating lease right-of-use assets | ||||
| Total assets | ||||
| Liabilities and shareholders’ deficit | ||||
| Current liabilities: | ||||
| Accounts payable | ||||
| Operating lease liabilities, current | ||||
| Accrued expenses and other current liabilities | ||||
| Bridge loans, net | ||||
| Total current liabilities | ||||
| Related party loan, non-current | ||||
| Share-settled contingent liability | ||||
| Warrant liabilities | ||||
| Operating lease liabilities, non-current | ||||
| Other non-current liabilities | ||||
| Total liabilities | ||||
| Shareholders’ deficit: | ||||
| Corporate capital | ||||
| Ordinary shares (€0.01 par value, 500,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 110,226,198 shares issued and outstanding as of June 30, 2026 and December 31, 2025) | ||||
| Convertible Preferred Shares (€100 par value, 8,040 shares authorized as of June 30, 2026 and December 31, 2025; 20 shares issued and outstanding as of June 30, 2026 and December 31, 2025) | ||||
| Additional paid-in capital | ||||
| Accumulated deficit | ||||
| Accumulated other comprehensive loss | ||||
| Total shareholders' deficit | ||||
| Total liabilities and shareholders’ deficit |
Loading...
